Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Allegretta

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Anti-Cancer Agents in Medicinal Chemistry|May 11, 2011
Therapeutic potential of targeting glypican-3 in hepatocellular carcinomaMark Allegretta, Jorge Filmus
Cancer|June 12, 2009
Glypican-3 protein expression in primary and metastatic melanoma: a combined immunohistochemistry and immunocytochemistry studyDina Kandil, Gladwyn Leiman, Mark Allegretta, et al.
Cancer|September 1, 2007
Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesionsDina Kandil, Gladwyn Leiman, Mark Allegretta, et al.
Environmental and Molecular Mutagenesis|March 4, 2005
HPRT mutations, TCR gene rearrangements, and HTLV-1 integration sites define in vivo T-cell clonal lineagesMark Allegretta, Stephanie K Ardell, Linda M Sullivan, et al.
Human Pathology|September 5, 2006
Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomasXiao Ying Wang, Françoise Degos, Sylvie Dubois, et al.
Biomaterials|May 20, 2014
Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibodyXiaoyang Yang, Hongguang Liu, Chris K Sun, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 3, 2022
Pathways to cures for multiple sclerosis: A research roadmapBruce F Bebo, Mark Allegretta, Douglas Landsman, et al.
Neurology|July 18, 2020
Serum neurofilament light as a biomarker in progressive multiple sclerosisRaju Kapoor, Kathryn E Smith, Mark Allegretta, et al.
Brain : a Journal of Neurology|May 18, 2026
Designing studies for post-treatment Lyme disease and other infection-associated chronic illnessesPaul M Arnaboldi, Jacqueline Becker, Avindra Nath, et al.
Nature Reviews. Neurology|July 15, 2022
From the prodromal stage of multiple sclerosis to disease preventionRuth Ann Marrie, Mark Allegretta, Lisa F Barcellos, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Anti-Cancer Agents in Medicinal Chemistry|May 11, 2011
Therapeutic potential of targeting glypican-3 in hepatocellular carcinomaMark Allegretta, Jorge Filmus
Cancer|June 12, 2009
Glypican-3 protein expression in primary and metastatic melanoma: a combined immunohistochemistry and immunocytochemistry studyDina Kandil, Gladwyn Leiman, Mark Allegretta, et al.
Cancer|September 1, 2007
Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesionsDina Kandil, Gladwyn Leiman, Mark Allegretta, et al.
Environmental and Molecular Mutagenesis|March 4, 2005
HPRT mutations, TCR gene rearrangements, and HTLV-1 integration sites define in vivo T-cell clonal lineagesMark Allegretta, Stephanie K Ardell, Linda M Sullivan, et al.
Human Pathology|September 5, 2006
Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomasXiao Ying Wang, Françoise Degos, Sylvie Dubois, et al.
Biomaterials|May 20, 2014
Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibodyXiaoyang Yang, Hongguang Liu, Chris K Sun, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 3, 2022
Pathways to cures for multiple sclerosis: A research roadmapBruce F Bebo, Mark Allegretta, Douglas Landsman, et al.
Neurology|July 18, 2020
Serum neurofilament light as a biomarker in progressive multiple sclerosisRaju Kapoor, Kathryn E Smith, Mark Allegretta, et al.
Brain : a Journal of Neurology|May 18, 2026
Designing studies for post-treatment Lyme disease and other infection-associated chronic illnessesPaul M Arnaboldi, Jacqueline Becker, Avindra Nath, et al.
Nature Reviews. Neurology|July 15, 2022
From the prodromal stage of multiple sclerosis to disease preventionRuth Ann Marrie, Mark Allegretta, Lisa F Barcellos, et al.
Pageof 1